University of Nebraska Medical Center Launches Patient Enrollment for RenovoRx's Pivotal Phase III TIGeR-PaC Clinical Trial

The TIGeR-PaC study is using RenovoRx's patented TAMP (Trans-Arterial Micro-Perfusion) therapy platform to evaluate its RenovoGem investigational drug-device combination product. RenovoGem utilizes pressuremediated delivery of chemotherapy across the arterial wall to bathe tumor tissue. The study is comparing treatment with TAMP to the current standard-of-care (systemic intravenous chemotherapy). "We are proud to partner with Dr. Klute and her team in our Phase III TIGeR-PaC trial," said Leesa Gentry, Chief ...